Skip to content
    Debiopharm Innovation Fund logo

    Debiopharm Innovation Fund

    Lausanne, SwitzerlandFounded 2006
    www.debiopharm.com/innovation-fundLinkedIn
    HealthcareBiotech & Life SciencesAIData & Analytics

    Debiopharm Innovation Fund is the corporate venture capital arm of Swiss biopharmaceutical company Debiopharm Group, headquartered in Lausanne. It invests in digital health, AI, and smart data startups transforming pharmaceutical R&D and cancer care, typically at seed and Series A stages.

    Their most common stage is series-a (69% of deals). Average disclosed round size is $12.4M (across 8 rounds with reported amounts).

    Find people at Debiopharm Innovation Fund on Goldilocks AI

    Portfolio

    15

    Fund Size

    $150M

    Top Stage

    Series A

    Last 12 Mo

    0

    Team

    MC

    Marc Cikes

    Managing Director, Debiopharm Innovation Fund S.A.

    AM

    Anne Marguerettaz

    Director, Cross-Company Project Coordination, Debiopharm Research & Manufacturing S.A.

    AT

    Antoine Touzet

    Director, Industrial Transposition, Debiopharm Research & Manufacturing

    CA

    Céline Anselmetti Dayer

    Director of Regulatory Affairs, Debiopharm Research & Manufacturing

    FP

    Fabrice Paradies

    Executive Director, Business Development & Global Commercial Alliances, Debiopharm Research & Manufacturing S.A.

    MS

    Marco Salvagni

    Executive Director, Operations, PMO & OpEx, Debiopharm Research & Manufacturing S.A.

    MC

    Moreno Centelleghe

    Technical Service & HSE Director, Debiopharm Research & Manufacturing S.A.

    OI

    Olivier Imboden

    Executive Director, Administration & HR, Debiopharm Research & Manufacturing S.A.

    PG

    Patrick Garrouste

    Executive Director, Drug Research & Development, Debiopharm Research & Manufacturing S.A.

    TL

    Thanh Liem Vu

    Director, Quality Assurance/Corporate Qualified Person, Debiopharm Research & Manufacturing S.A.

    TG

    Tom Gibbs

    Senior Investment Director, Debiopharm Innovation Fund S.A.

    VL

    Vincent Lepreux

    Investment Director, Debiopharm Innovation Fund S.A.

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    16 investments
    CompanyRoundAmountDate
    Altis Labs logoAltis LabsSeed$6MJun 2023
    Genialis logoGenialisSeries A$13MMar 2023
    Iktos logoIktosSeries A—Mar 2023
    Yonalink logoYonalinkSeed$6MNov 2022
    WhiteLab Genomics logoWhiteLab GenomicsSeries A$10MSep 2022
    Vivosense logoVivosenseSeries A$25MJan 2022
    CCareviveSeries C$18MJan 2021
    OOncomfortSeries A—Sep 2020
    CCarevive SystemsSeries C—Feb 2020
    NNovadiscoverySeries A—Jan 2020
    Verisim Life logoVerisim LifeSeries A$15MAug 2019
    Kaiku logoKaikuSeries A—Apr 2018
    KKaiku HealthSeries A—Apr 2018
    Yonalink logoYonalinkGrowth$6M—
    FFosanisSeries A——
    Kaiku logoKaikuSeries A——

    Top Co-Investors

    W Health Ventures3 shared
    Tesi3 shared
    Reaktor3 shared
    Omnes Capital2 shared
    HLM Investment Partners2 shared
    LRVHealth2 shared
    Philips Ventures2 shared
    M Ventures1 shared
    Taiwania Capital Management Corporation1 shared
    Redalpine1 shared
    First Star Ventures1 shared
    Plug and Play Tech Center1 shared
    Morpheus Ventures1 shared
    Village Global1 shared
    Intel Capital1 shared
    OCA Ventures1 shared
    Deepwater Asset Management1 shared
    Susa Ventures1 shared
    Perceptive Xontogeny Venture Fund1 shared
    Perceptive Advisors1 shared

    Last updated: 7 October 2026